Peak 2013 corporate bonds complete principal and interest payments
Release time:
2020-07-31
News 11# May 20 , Zhejiang Jianfeng Group Co., Ltd. 2013 Corporate Bonds (Phase II) (hereinafter referred to as "13 Peak 02 ") was successfully paid. At this point, all the corporate bonds approved for issue in Spike 2013 have been paid.
In 2013 , with the approval of document [2013]595 of China Securities Regulatory Commission, the company was allowed to issue corporate bonds with a face value not exceeding .4 billion yuan to the public, with a debt rating of AA +. 2013 6 5 , the company issued 2013 corporate bonds (the first issue) (hereinafter referred to as "13 peak 01 "), raising 3 .2 billion yuan at the coupon rate of 4.90% , it was 1.55 percentage points lower than the benchmark bank loan rate of 5 years at that time. 2014 11 20 , "13 peak 02 " was successfully issued, raising 3 billion yuan again at the coupon rate of 5.09% , it was listed and traded on the Shanghai Stock Exchange on 2014 12 April 11 . The ability to raise $.8 billion from the capital market at a lower cost reflects investors' recognition of the company's "Cement +Pharmaceutical" dual-business structure and expectations of the company's good operating results.
2018 6 July 5 , Jianfeng Group 2013 first issue of corporate bonds due to complete the principal and interest payment, and now the second issue of corporate bonds also successfully completed the principal and interest payment. At a time when the growth of the real economy is weak and the business operations are constantly exploding, the company has successfully completed two phases of principal and interest payment of .3 billion yuan corporate bonds in a short period of time, fully reflecting the company's good operating efficiency and strong financial strength in recent years.
Six years have passed since the company's first corporate bond issuance. These six years have been the fastest and most stable six years in the history of Jianfeng Group's operating performance. By the end of the third quarter of 2019 , the total assets of the company reached 54.97 .1 billion yuan, up 71.51 from 32.05 9.5 billion yuan at the end of 2013 ; The net assets returned to the parent reached 36.41 .9 billion yuan, up 109.61% from 101 2013 17.37 .3 billion yuan at the end of ; 's annual operating income in 2018 reached 33.62 .9 billion yuan, up 56.30 from 's 21.51 .3 billion yuan in 2013 . Net profit attributable to the parent reached 5.89 .7 billion yuan, up 91.58 from 2.02 .1 billion yuan in 2013 . This is not only due to the company's long-term adherence to the strategy of "cooperative innovation to strengthen the main business, standardize science and seek development", but also due to the company's focus on industry, adhere to the main business, and actively develop and expand the two main businesses of cement and medicine.
The smooth payment of the principal and interest of the company's bonds has further improved the company's credibility, strengthened investors' confidence in the company, established a good corporate image in the capital market, and contributed to the company's sustained, stable and healthy Development has laid a solid foundation. (residual fruit)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page